Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors
Orano Med, a clinical stage radiopharmaceutical company, has announced that the first patient has been dosed in a Phase 1 trial of the alpha radioligand therapy with lead-212, 212Pb-GRPR, in patients with advanced solid tumors that express gastrin-releasing peptide receptor (GRPR). 212Pb-GRPR is the first targeted alpha therapy (TAT) targeting GRPR, a protein located on the surface of cells that is highly expressed in prostate cancer, lung cancer, breast cancer and other solid tumors.
“Dosing the first patient in our Phase I 212Pb-GRPR clinical trial is a key development milestone for Orano Med in our strategy to develop a pipeline of alpha radiopharmaceuticals targeting difficult-to-treat cancers,” said Julien Dodet, Chief Executive Officer. “The short-range cancer cell killing capabilities of alpha-emitting radioisotopes could mean there is limited toxicity to surrounding healthy cells. Based on promising preclinical results with 212Pb-GRPR, we believe that this first alpha therapy targeting GRPR could significantly improve outcomes for cancer patients who have exhausted other therapies.”
212Pb-GRPR is being evaluated in an ongoing, multi-center, single arm, non-randomized, open-label basket trial that will enroll approximately 30 patients with advanced solid tumors. It includes a dose escalation phase followed by an expansion phase. The primary endpoint is to evaluate the safety and tolerability of 212Pb-GRPR. Exploratory efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) using RECIST v1.1 criteria. Additional information about the trial, which is recruiting patients, can be found on clinicaltrials.gov: NCT 05283330.
“We are convinced that targeted alpha therapies, such as 212Pb-GRPR, are the future of radiopharmaceutical therapies, providing an increased cytotoxic potential against cancer cells and the ability to improve treatments in areas of high unmet needs. We were excited about the success of recent beta emitters but believe that alpha radiopharmaceutical therapies will be the next more effective game changer, which will advance the field significantly,” said Michael Morris, MD, Founder & Medical Director of Advanced Molecular Imaging and Therapy, the specialist center where the first patient was dosed.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more